Brii Biosciences Limited (2137.HK)
HKD 0.85
(0.0%)
HKD 0.85
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.15 Million CNY | -75.06% |
| 2022 | 12.65 Million CNY | -41.45% |
| 2021 | 21.61 Million CNY | -23.69% |
| 2020 | 28.32 Million CNY | -19.33% |
| 2019 | 35.11 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - CNY | 0.0% |
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q2 | 7.99 Million CNY | 0.0% |
| 2023 FY | 3.15 Million CNY | -75.06% |
| 2023 Q4 | 3.15 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2022 Q2 | 17.47 Million CNY | 112.96% |
| 2022 Q1 | 8.2 Million CNY | -62.05% |
| 2022 FY | 12.65 Million CNY | -41.45% |
| 2022 Q4 | 12.65 Million CNY | 301.01% |
| 2022 Q3 | 3.15 Million CNY | -81.94% |
| 2021 Q3 | 12.64 Million CNY | -53.86% |
| 2021 FY | 21.61 Million CNY | -23.69% |
| 2021 Q1 | 6.14 Billion CNY | 21587.23% |
| 2021 Q2 | 27.41 Million CNY | -99.55% |
| 2021 Q4 | 21.61 Million CNY | 70.92% |
| 2020 FY | 28.32 Million CNY | -19.33% |
| 2020 Q3 | 2.42 Billion CNY | 0.0% |
| 2020 Q4 | 28.32 Million CNY | -98.83% |
| 2020 Q1 | - CNY | 0.0% |
| 2019 FY | 35.11 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | 94.03% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 99.947% |